Johnson & Johnson Stock News

Johnson & Johnson said on Monday its experimental use of Caplyta for bipolar mania met the main goal ​of a late-stage study, bringing the drug a step ‌closer to expanding beyond its currently approved uses.

Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxis Fewer than 1% of patients discontinued treatment due to treatment-related events at one year New findings from Johnson & Johnson build on the MARIPOSA survival benefit and strengthen evidence for RYBREVANT FASPRO plus LAZCLUZE as first-line treatment SEOUL, South Korea, ...

Contineum Therapeutics said on Monday an experimental depression drug it developed with Johnson & ​Johnson failed to meet the main goal ‌of a mid-stage study.

RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET Results mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8% SEOUL, South Korea, Sept. 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results from the final overall survival (OS) analys...

The health-products company said it planned to hive off its DePuy Synthes unit to focus on higher-growth areas.

Apollo Global ​Management is ‌in discussions to acquire ​Johnson & ​Johnson's orthopedics unit ⁠in ​a deal ​that could value the unit ​at ​close to $20 billion, ‌Bloomberg ⁠News reported on Friday, ​citing ​sources.

LIMERICK, Ireland--(BUSINESS WIRE)--Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX 2-Week, a new reusable contact lens featuring proprietary MAX technologies.

First presentation of pivotal Phase 3 CAPLYTA ® data in adults with bipolar mania underscores the asset's potential across mood disorders New SPRAVATO ® analyses and schizophrenia research emphasize a focus on complex, high-burden neuropsychiatric conditions TITUSVILLE, N.J., Sept. 8, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that 24 abstracts featuring clinical data an...